Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1540515

registered interest
date	08/11/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Olaparib
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department is taking steps to make Olaparib available on the NHS for people with prostate cancer.
tabling member constituency	Warrington South
tabling member printed	Andy Carter
uin	82462
answer	answer is ministerial correction date of answer 15/11/2022 answer text <p>In October 2022, the National Institute for Health and Care Excellence (NICE) published guidance which does not recommend olaparib for the treatment of prostate cancer. ‘Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer’ is available at the following link:</p><p><a href="https://www.nice.org.uk/guidance/ta831" target="_blank">https://www.nice.org.uk/guidance/ta831</a></p><p>NICE continues to survey new evidence which may affect its published guidance and would consult on proposed changes with a wide range of stakeholders if significant new evidence were to emerge.</p> answering member constituency Colchester answering member printed Will Quince question first answered 15/11/2022 14:36:13 answering member 4423 label Biography information for Will Quince
tabling member	4791 label Biography information for Andy Carter

1490521

registered interest
date	19/07/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Bowel Cancer: Bevacizumab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department plans to take steps to make Avastin available on the NHS for people with stage 3 or 4 bowel cancer.
tabling member constituency	Warrington South
tabling member printed	Andy Carter
uin	40009
answer	answer is ministerial correction date of answer 26/07/2022 answer text <p>Bevacizumab (Avastin) is not routinely funded on the National Health Service in England. In 2012, the National Institute for Health and Care Excellence (NICE) considered the clinical and cost-effectiveness of bevacizumab for the treatment of metastatic colorectal cancer in adults. However, it was unable to recommend the drug as an effective use of resources. NICE monitors new evidence which may affect its guidance and would consult on proposed changes with stakeholders if any such evidence emerges.</p><p>Where a treatment is not routinely commissioned by the NHS, a patient’s clinician may submit an individual funding request if they consider it is in the patient’s best interests.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 26/07/2022 16:26:12 answering member 4492 label Biography information for Maria Caulfield
tabling member	4791 label Biography information for Andy Carter